Fig. 3

In vivo efficacy study of bosutinib-HDL NPs and radiation in heterotopic MOC-1 HNSCC tumour bearing murine model. A Tumour size during in vivo efficacy study. Bosutinib-HDL NPs and/or radiation treatment sessions are shown by dotted lines on the graph. Data is represented as mean ± standard error of the mean. Some mice were euthanised earlier than the study endpoint due to tumour ulceration complications, which is associated with fluctuations in the average tumour size in the control group (indicated with an arrow in the graph). Two way ANOVA and Tukey multiple comparisons test were used for statistical analysis (α = 0.05). B ¹⁸F-FDG PET images of mice approximately represent the average TLG% for each treatment group. The tumour location is depicted with an arrow (coronal section, tail and head are oriented toward the top and bottom of the image, respectively). ¹⁸F-FDG activity is represented as kBq/cc. C, D ¹⁸F-FDG TLG% and SUV% after 6 sessions of bosutinib-HDL NPs and radiation treatment (5 mice per treatment group). One way ANOVA and Tukey multiple comparisons test were used for statistical analysis (α = 0.05)